LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

8.55 -3.5

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.54

Max

8.9

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M -20M
Verkäufe	5.9M 40M
EPS	-0.19
Gewinnspanne	-49.569
Angestellte	184
EBITDA	16M -19M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+167.84% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	159M 908M
Vorheriger Eröffnungskurs	12.05
Vorheriger Schlusskurs	8.55

Nachrichtenstimmung

By Acuity

50%

190 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Nov. 2025, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18. Nov. 2025, 18:09 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18. Nov. 2025, 17:39 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18. Nov. 2025, 16:25 UTC

Wichtige Markttreiber

Diginex Rises on Deal With Digital Asset Platform Evident

18. Nov. 2025, 23:56 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18. Nov. 2025, 23:39 UTC

Market Talk

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18. Nov. 2025, 22:59 UTC

Market Talk

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18. Nov. 2025, 22:08 UTC

Market Talk

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18. Nov. 2025, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18. Nov. 2025, 22:03 UTC

Ergebnisse

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. Nov. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. Nov. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Nov. 2025, 21:15 UTC

Market Talk

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18. Nov. 2025, 20:46 UTC

Market Talk

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18. Nov. 2025, 20:13 UTC

Market Talk

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18. Nov. 2025, 19:48 UTC

Market Talk

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18. Nov. 2025, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18. Nov. 2025, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18. Nov. 2025, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18. Nov. 2025, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18. Nov. 2025, 18:29 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. Nov. 2025, 18:18 UTC

Market Talk

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18. Nov. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Nov. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

18. Nov. 2025, 17:19 UTC

Market Talk

Ergebnisse

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18. Nov. 2025, 17:06 UTC

Ergebnisse

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18. Nov. 2025, 16:06 UTC

Akquisitionen, Fusionen, Übernahmen

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18. Nov. 2025, 15:59 UTC

Ergebnisse

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18. Nov. 2025, 15:35 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18. Nov. 2025, 15:35 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

167.84% Vorteil

12-Monats-Prognose

Durchschnitt 23.57 USD 167.84%

Hoch 34 USD

Tief 16 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

190 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.